ClinicalTrials.gg
CompletedNCT04974528INHALE-1Updated May 6, 2025

Afrezza® INHALE-1 Study in Pediatrics

A Phase 3 interventional study of Afrezza and Rapid-acting Insulin Analog in Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2, sponsored by Mannkind Corporation. Completed at 39 sites in United States. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-05-06.

Sponsored by Mannkind Corporation · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2024, 2 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
319
Allocation
Randomized
Ages
4 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 1.

Enrollment
10th of 35
319 · median 74
Started
2021
the only one that year
Phase 3
17 of 35
none open now
Registered
32nd of 35
by date
Lead sponsor
14 of 35
Mannkind Corporation

Among the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, this one is the 10th largest by enrollment, is the only one that started in 2021, is one of 17 in phase 3, and was the 32nd registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

1 of the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 4 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

INHALE-1 is a Phase 3, open-label, randomized clinical study evaluating the efficacy and safety of Afrezza in combination with a basal insulin (i.e., the Afrezza group) versus insulin aspart, insulin lispro or insulin glulisine in combination with a basal insulin (i.e., the Rapid-acting Insulin Analog [RAA] injection group) in pediatric subjects with type 1 or type 2 diabetes mellitus. Following 26 weeks of randomized treatment (i.e., Afrezza or RAA injection combined with a basal insulin), all subjects will enter a treatment extension where subjects will receive Afrezza until Week 52. The purpose of the treatment extension is to assess safety and efficacy with continued use of Afrezza.

Pediatric subjects ≥4 and \<18 years of age will be enrolled in this study. Subjects will be randomly assigned in a 1:1 ratio to either the Afrezza group or the RAA injection group.

The study is composed of:

  • Up to 5-week screening/run-in period
  • 26 week randomized treatment period
  • 26-week treatment extension
  • 4-week follow-up period
03

Conditions studied

  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2

Keywords

  • Diabetes Mellitus
  • Insulin
  • Inhaled
  • Afrezza
  • Technosphere
  • Pediatric
04

Who can participate

Ages eligible
4 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Assent from the pediatric subject, as appropriate, and fully from the parent(s) or legal guardian, as required by both state and federal laws and the local Institutional Review Board (IRB)
  • Subjects ≥4 and \<18 years of age
  • Clinical diagnosis of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) per the Investigator and have been using insulin for at least 6 months for T1DM, or at least 3 months for T2DM
  • Treatment with basal-bolus insulin therapy delivered by multiple daily injections for at least 2 weeks
  • Bolus insulins are restricted to the RAAs insulin lispro, insulin aspart or insulin glulisine, including biosimilar products
  • Basal insulins are restricted to insulin glargine, insulin degludec or insulin detemir, including biosimilar products
  • Access to stable WiFi connection
  • ≥7.0% and ≤11%
  • Average prandial dose of insulin ≥2 units per meal
  • Utilized CGM for ≥70% of the time over a consecutive 14-day period preceding randomization

Exclusion criteria

Exclusion Criteria:

  • History of recent blood transfusions (within previous 3 months), hemoglobinopathies, or any other conditions that affect measurements
  • Recent history of asthma (defined as using any medications to treat within the last year), any other pulmonary disease (e.g., cystic fibrosis or bronchopulmonary dysplasia), or significant congenital or acquired cardiopulmonary disease
  • History of serious complications of diabetes (e.g., active proliferative retinopathy or symptomatic autonomic neuropathy), or likely need for specific treatment for diabetic retinopathy (laser photocoagulation, vitrectomy, other) in the next year
  • and FEV1/forced vital capacity (FVC) ≤80% of predicted Global Lung Function Initiative (GLI) value
  • Inability to achieve an acceptable FEV1 and FVC reading for subjects ≥8 years of age would make the subject ineligible
  • For subjects \<8 years of age who are unable to achieve an acceptable FVC reading, FEV1 only may be assessed; inability to achieve an acceptable FEV1 would make the subject ineligible
  • Respiratory tract infection within 14 days before screening (subject may return 14 days after resolution of symptoms for rescreening)
  • Inability or unwillingness to perform study procedures
  • Exposure to any product(s), including drugs or devices, in the past 30 days
  • Any disease other than diabetes or exposure to any medication that, in the judgment of the Investigator, may impact glucose metabolism and current or anticipated acute uses of or weight loss medications, with the exception of metformin and/or GLP-1 agonists (if GLP-1 agonists used for at least the 3 months prior to enrollment) in subjects with T2DM
  • Use of antiadrenergic drugs (e.g., clonidine)
  • Any concurrent illness (other than diabetes mellitus) not controlled by a stable therapeutic regimen
  • Current uncontrolled eating disorder (e.g., anorexia or bulimia nervosa)
  • Current drug or alcohol abuse or a history of drug or alcohol abuse that, in the opinion of the Investigator or the Sponsor, would make the subject an unsuitable candidate for participation in the study
  • Smoking (includes cigarettes, cigars, pipes, marijuana, and vaping devices) for the preceding 6 months and/or positive urine cotinine test
  • Female subject who is pregnant, breast-feeding, intends to become pregnant, or is of , sexually active and not using adequate methods as required by local regulation or practice
  • An event of severe hypoglycemia, as judged by the Investigator, within the last 90 days prior to screening
  • An episode of DKA requiring hospitalization within the last 90 days prior to screening
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
319 participants (actual)

Study arms

  • Experimental
    Afrezza (Technosphere Insulin) + Basal Insulin

    Individualized dose of Afrezza (Technosphere Insulin) for each patient before each meal (breakfast, lunch, and dinner) for 26 weeks. Individualized basal insulin (insulin degludec, insulin glargine or insulin detemir) for each patient.

    Biological: Afrezza · Biological: Basal Insulin

  • Active comparator
    RAA Injection + Basal Insulin

    Individualized dose of RAA injection (insulin aspart, insulin lispro or insulin glulisine) for each patient for 26 weeks. Individualized basal insulin (insulin degludec, insulin glargine or insulin detemir) for each patient.

    Biological: Rapid-acting Insulin Analog · Biological: Basal Insulin

Interventions

  • BiologicalAfrezza

    Pharmaceutical form: powder Route of administration: inhalation

    Also known as: Technosphere Insulin

  • Pharmaceutical form: clear and colorless solution for injection Route of administration: subcutaneous

    Also known as: insulin aspart, insulin lispro, insulin glulisine, Novolog®, Fiasp®, Humalog®, Admelog®, Apidra®

  • BiologicalBasal Insulin

    Pharmaceutical form: solution for injection Route of administration: subcutaneous

    Also known as: insulin glargine, insulin degludec, insulin detemir, Lantus®, Abasaglar®, Basaglar®, Semglee®, Toujeo®, Tresiba®, Levemir®

06

What researchers measure

Primary outcomes

  1. Change in HbA1c

    Change in HbA1c from baseline to Week 26, for noninferiority assessment

    Time frame: 26 weeks

Secondary outcomes

  1. Change in Fasting Plasma Glucose (FPG)

    Change in FPG from baseline to Week 26, for superiority assessment

    Time frame: 26 weeks

  2. Event rate of pooled level 2 and level 3 hypoglycemia

    Event rate of pooled level 2 and level 3 hypoglycemia (SMBG \< 54 mg/dL and/or severe hypoglycemic events reported on the adverse event CRF) during the 26 -week randomized treatment period, for superiority assessment.

    Time frame: 26 weeks

  3. Change in HbA1c

    Change in HbA1c from baseline to Week 26, for superiority assessment

    Time frame: 26 weeks

Other outcomes

  1. Event rate of level 1 hypoglycemia (SMBG <70 mg/dL)

    Event rate of level 1 hypoglycemia during the 26-week randomized treatment period

    Time frame: 26 weeks

  2. Change in percent Time In Range (glucose 70 - 180 mg/dL)

    Change in percent Time In Range from baseline to Week 26, using Continuous Glucose Monitoring (CGM)-derived data collected over the preceding 30 days for the 24-hour, daytime and nocturnal time periods

    Time frame: 26 weeks

  3. Change in percent time with glucose <54 mg/dL

    Change in percent time with glucose \<54 mg/dL from baseline to Week 26, using CGM-derived data collected over the preceding 30 days for the 24-hour, daytime and nocturnal time periods

    Time frame: 26 weeks

  4. Change in percent Time Below Range (glucose <70 mg/dL)

    Change in percent Time Below Range from baseline to Week 26, using CGM-derived data collected over the preceding 30 days for the 24-hour, daytime and nocturnal time periods

    Time frame: 26 weeks

  5. Change in percent Time Above Range (glucose >180 mg/dL)

    Change in percent Time Above Range from baseline to Week 26, using CGM-derived data collected over the preceding 30 days for the 24-hour, daytime and nocturnal time periods

    Time frame: 26 weeks

  6. Percentage of subjects with HbA1c <7.0%

    Percentage of subjects with HbA1c \<7.0% at Week 26

    Time frame: At Week 26

  7. Score of Diabetes Treatment Satisfaction Questionnaire (DTSQ) Change (c)-Teen

    Score of DTSQ(c)-Teen at Week 26 in the Afrezza group (score ranges from -24 to 24, with higher score means greater satisfaction)

    Time frame: At Week 26

  8. Score of Diabetes Treatment Satisfaction Questionnaire (DTSQ) Change (c)-Parent

    Score of DTSQ(c)-Parent at Week 26 in the Afrezza group (score ranges from -30 to 30, with higher score means greater satisfaction)

    Time frame: At Week 26

  9. Change in scores of DTSQ Status (s)-Teen

    Change in scores of DTSQ(s)-Teen from baseline to Week 26 (change in score ranges from -48 to 48, with higher score means greater satisfaction)

    Time frame: 26 weeks

  10. Change in scores of DTSQ Status (s)-Parent

    Change in scores of DTSQ(s)-Parent from baseline to Week 26 (change in scores ranges from -60 to 60, with higher score means greater satisfaction)

    Time frame: 26 weeks

  11. Change in HbA1c

    Change in HbA1c from baseline to Week 52 (and change from Week 26 to Week 52 if required) in subjects who switch from treatment with RAA injections to Afrezza at Week 26

    Time frame: 52 weeks (and 26 weeks if required)

  12. Change in FPG

    Change in FPG from baseline to Week 52 (and change from Week 26 to Week 52 if required) in subjects who switch from treatment with RAA injections to Afrezza at Week 26

    Time frame: 52 weeks (and 26 weeks if required)

  13. Change in percent Time In Range, Time Below Range and Time Above Range

    Change in percent Time In Range, Time Below Range and Time Above Range from baseline to Week 52 (and change from Week 26 to Week 52 if required) in subjects who switch from treatment with RAA injections to Afrezza at Week 26; using CGM-derived data collected over the preceding 30 days for the 24-hour, daytime, and nocturnal periods

    Time frame: 52 weeks (and 26 weeks if required)

  14. Change in HbA1c

    Change in HbA1c from baseline to Week 52 in subjects who receive Afrezza in both the randomized treatment period and the treatment extension

    Time frame: 52 weeks

  15. Change in FPG

    Change in FPG from baseline to Week 52 in subjects who receive Afrezza in both the randomized treatment period and the treatment extension

    Time frame: 52 weeks

  16. Change in percent Time In Range, Time Below Range and Time Above Range

    Change in percent Time In Range, Time Below Range and Time Above Range from baseline to Week 52 in subjects who receive Afrezza in both the randomized treatment period and the treatment extension; using CGM-derived data collected over the preceding 30 days for the 24-hour, daytime, and nocturnal periods

    Time frame: 52 weeks

  17. Score of DTSQ(c)-Teen at Week 52

    Score of DTSQ(c)-Teen at Week 52 (after 6 months of Afrezza treatment) in subjects who switch from RAA injections to Afrezza (score ranges from -24 to 24, with higher score means greater satisfaction)

    Time frame: At Week 52

  18. Score of DTSQ(c)-Parent at Week 52

    Score of DTSQ(c)-Parent at Week 52 (after 6 months of Afrezza treatment) in subjects who switch from RAA injections to Afrezza (score ranges from -30 to 30, with higher score means greater satisfaction)

    Time frame: At Week 52

  19. Change in scores of DTSQ(s)-Teen

    Change in scores of DTSQ(s)-Teen from baseline to Week 52 (changes in score ranges from -48 to 48, with higher score means greater satisfaction)

    Time frame: 52 weeks

  20. Change in scores of DTSQ(s)-Parent

    Change in scores of DTSQ(s)-Parent from baseline to Week 52 (change in scores ranges from -60 to 60, with higher score means greater satisfaction)

    Time frame: 52 weeks

  21. Event rates of hypoglycemic events

    Event rates and incidence of total, nocturnal, and severe hypoglycemic events from baseline to Week 52

    Time frame: 52 weeks

  22. Incidence of hypoglycemic events

    Incidence of total, nocturnal, and severe hypoglycemic events from baseline to Week 52

    Time frame: 52 weeks

  23. Incidence and severity of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Incidence and severity of TEAEs and SAEs from baseline to Week 52

    Time frame: 52 weeks

  24. Incidence and severity of Adverse Events of Special Interest (AESIs)

    Incidence and severity of AESIs (i.e., acute bronchospasm, clinically relevant decline in pulmonary function \[\>15% decline from baseline percent predicted FEV1 accompanied by respiratory symptoms\], hypersensitivity reactions \[including anaphylaxis\], use of asthma reliever medication, initiation or use of asthma controller medication, use of corticosteroid bursts, asthma exacerbations, hospitalization for asthma exacerbation, events of level 3 hypoglycemia, and diabetic ketoacidosis \[DKA\]) as well as the number of subjects with AESIs and number of individual events

    Time frame: 52 weeks

  25. Change in percent predicted Forced Expiratory Volume in 1 Second (FEV1)

    Change from baseline to Weeks 13, 26, 39, 52, and 56 in percent predicted FEV1

    Time frame: 56 weeks

07

Study locations

39 sites
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Children's Hospital of Orange County
    Orange, California 92868, United States
  • Stanford University
    Palo Alto, California 94304, United States
  • Sutter Institute for Medical Research (formerly Center of Excellence in Diabetes and Endocrinology)
    Sacramento, California 95821, United States
  • University of California San Diego, Rady Children's Hospital
    San Diego, California 92123, United States
  • University of California San Francisco
    San Francisco, California 94158, United States
  • Yale New Haven Hospital
    New Haven, Connecticut 06511, United States
  • Nemours Children's Hospital, Delaware
    Wilmington, Delaware 19803, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • Joe DiMaggio Children's Hospital
    Hollywood, Florida 33021, United States
  • Advent Health Orlando
    Orlando, Florida 32803, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Emory University, Children's Healthcare of Atlanta
    Atlanta, Georgia 30329, United States
  • Rocky Mountain Clinical Research
    Idaho Falls, Idaho 83404, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Iowa Diabetes Research, IDR
    West Des Moines, Iowa 50265, United States
  • University of Louisville, Norton Children's Hospital
    Louisville, Kentucky 40202, United States
  • Dr. Barry J. Reiner
    Baltimore, Maryland 21229, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • Joslin Diabetes Center
    Boston, Massachusetts 02215, United States
  • Michigan Pediatric Endocrine and Diabetes Services
    Livonia, Michigan 48152, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Children's Mercy Hospital
    Kansas City, Missouri 64111, United States
  • The DOCS
    Las Vegas, Nevada 89113, United States
  • Atlantic Health
    Morristown, New Jersey 07960, United States
  • UBMD Pediatrics Buffalo
    Buffalo, New York 14203, United States
  • NYU Langone, Hassenfeld Children's Hospital
    New York, New York 10016, United States
  • Cincinnati Children's Hospital
    Cincinnati, Ohio 45229, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Oklahoma Children's Hospital
    Oklahoma City, Oklahoma 73104, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • AM Diabetes and Endocrinology Center
    Bartlett, Tennessee 38133, United States
  • UT Southwestern
    Dallas, Texas 75390, United States
  • DHR Health
    Edinburg, Texas 78539, United States
  • Diabetes & Glandular Disease Clinic, DGD
    San Antonio, Texas 78229, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Seattle Children's
    Seattle, Washington 98105, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53201, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Oct 2024, 36 months.

Of 79 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's 36 months is above that.

Counting every sponsor, half of 108 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2021
First posted
Jul 23, 2021
StartActual
Sep 29, 2021
Primary completionActual
Oct 3, 2024
CompletionActual
Apr 29, 2025
Last update
May 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04974528
Responsible party
Sponsor
First posted
Jul 23, 2021
Start date
Sep 29, 2021
Primary completion
Oct 3, 2024
Completion
Apr 29, 2025
Last update
May 6, 2025

Study contacts

Kevin Kaiserman
study director · Mannkind Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion